{"id":"xermelo","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"13%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Increased gamma-glutamyl-transferase (GGT)","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Decreased appetite","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Increased alkaline phosphatase","drugRate":"","severity":"uncommon","organSystem":""},{"effect":"Increased alanine aminotransferase","drugRate":"","severity":"uncommon","organSystem":""},{"effect":"Increased aspartate aminotransferase","drugRate":"","severity":"uncommon","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Fecaloma","drugRate":"2.2%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL3348963","moleculeType":"Small molecule","molecularWeight":"754.17"},"aliases":["Telotristat ethyl"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"f11c21f8-f725-445e-b38e-1e4c5b05bcc6","title":"XERMELO (TELOTRISTAT ETHYL) TABLET [LEXICON PHARMACEUTICALS, INC.]"},"ecosystem":[],"mechanism":{"target":"Tryptophan 5-hydroxylase 1"},"_scrapedAt":"2026-03-28T02:58:03.494Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Diarrhea","diseaseId":"diarrhea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04810091","phase":"PHASE3","title":"Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-18","conditions":"Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm","enrollment":79},{"nctId":"NCT03910387","phase":"PHASE2","title":"Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-04-17","conditions":"Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma","enrollment":23},{"nctId":"NCT03453489","phase":"PHASE2","title":"AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2018-06-20","conditions":"Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm","enrollment":4},{"nctId":"NCT03223428","phase":"","title":"Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO","status":"COMPLETED","sponsor":"TerSera Therapeutics LLC","startDate":"2017-06-22","conditions":"Carcinoid Syndrome","enrollment":223},{"nctId":"NCT04543955","phase":"PHASE2","title":"Telotristat With Lutathera in Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Lowell Anthony, MD","startDate":"2021-09-13","conditions":"Neuroendocrine Tumors","enrollment":1},{"nctId":"NCT03790111","phase":"PHASE2","title":"A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer","status":"TERMINATED","sponsor":"TerSera Therapeutics LLC","startDate":"2019-03-13","conditions":"Biliary Tract Cancer (BTC)","enrollment":53},{"nctId":"NCT04713202","phase":"PHASE2","title":"Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl","status":"WITHDRAWN","sponsor":"Chandrikha Chandrasekhara","startDate":"2021-03-03","conditions":"Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea","enrollment":""},{"nctId":"NCT04672876","phase":"PHASE2","title":"Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-01","conditions":"Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT04776876","phase":"PHASE2","title":"Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-01","conditions":"Advanced Neuroendocrine Neoplasm, Carcinoid Syndrome","enrollment":""},{"nctId":"NCT04034745","phase":"","title":"Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain","status":"WITHDRAWN","sponsor":"Andrew Hendifar, MD","startDate":"2020-10","conditions":"Pancreatic Cancer, Neuroendocrine Tumors, Cachexia; Cancer","enrollment":""},{"nctId":"NCT03442725","phase":"PHASE1","title":"Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function","status":"COMPLETED","sponsor":"Ipsen","startDate":"2018-02-09","conditions":"Renal Impairment","enrollment":16},{"nctId":"NCT04065165","phase":"PHASE3","title":"Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2020-04","conditions":"Small Intestinal NET, Carcinoid Heart Disease","enrollment":""},{"nctId":"NCT02026063","phase":"PHASE3","title":"Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-01-14","conditions":"Carcinoid Syndrome","enrollment":124},{"nctId":"NCT01456052","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2012-01-30","conditions":"Ulcerative Colitis","enrollment":59},{"nctId":"NCT01104415","phase":"PHASE2","title":"Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2010-06-15","conditions":"Carcinoid Syndrome","enrollment":15},{"nctId":"NCT02683577","phase":"PHASE1","title":"Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects","status":"COMPLETED","sponsor":"Ipsen","startDate":"2016-02","conditions":"Hepatic Impairment","enrollment":24},{"nctId":"NCT00853047","phase":"PHASE2","title":"Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2009-03","conditions":"Carcinoid Syndrome","enrollment":23},{"nctId":"NCT03423446","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-11-28","conditions":"Hepatic Impairment","enrollment":16},{"nctId":"NCT03302845","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-09-21","conditions":"Drug-drug Interaction","enrollment":32},{"nctId":"NCT01677910","phase":"PHASE3","title":"TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2013-01-08","conditions":"Carcinoid Syndrome","enrollment":135},{"nctId":"NCT02063659","phase":"PHASE3","title":"Telotristat Etiprate for Carcinoid Syndrome Therapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-03-11","conditions":"Carcinoid Syndrome","enrollment":76},{"nctId":"NCT02195635","phase":"PHASE1","title":"Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-07","conditions":"Drug Interactions","enrollment":24},{"nctId":"NCT02147808","phase":"PHASE1","title":"A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-05","conditions":"Drug Interactions","enrollment":24},{"nctId":"NCT02155205","phase":"PHASE1","title":"A Thorough QT Study of Telotristat Etiprate","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-05","conditions":"QT Interval","enrollment":48},{"nctId":"NCT02157584","phase":"PHASE1","title":"An Open-Label Food Effect Study of Telotristat Etiprate","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-06","conditions":"Healthy","enrollment":22},{"nctId":"NCT02157558","phase":"PHASE1","title":"An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-07","conditions":"Drug Interactions","enrollment":24},{"nctId":"NCT01932528","phase":"PHASE1","title":"An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2013-08","conditions":"Carcinoid Syndrome","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Xermelo","genericName":"Xermelo","companyName":"TerSera Therapeutics LLC","companyId":"tersera-therapeutics-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}